Clinical References on Macadamia (Macadamia alternifolia)
Ako H, et al. Healthful new oil from macadamia nuts. (Nutrition, 1995 May-Jun
(Abstract Available)
Nestel P, et al. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. J Lipid Res, 1994 Apr
(Abstract Available)
Healthful new oil from macadamia nuts.
Ako H; Okuda D; Gray D
Department of Environmental Biochemistry, University of Hawaii, Honolulu 96822, USA.
Nutrition, 11: 3, 1995 May-Jun, 286-8
Abstract
Fatty acid profiles were obtained for macadamia nut oil and several other cooking oils. Macadamia nut oil contained the highest level (79%) of monounsaturated fatty acids. Macadamia nut oil is low (4%) in the omega-6 fatty acid 18:2n-6 and saturated fatty acids. Fatty acid profiles for popcorn cooked in several oils were obtained for comparison because of public awareness and concern over high levels of saturated fat found in popcorn sold in theaters. The nutritional implications of using macadamia nut oil are discussed.
Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men.
Nestel P; Clifton P; Noakes M
CSIRO Division of Human Nutrition, Adelaide, Australia.
J Lipid Res, 35: 4, 1994 Apr, 656-62
Abstract
Palmitoleic acid is a minor monounsaturated fatty acid in the human diet and in blood plasma. Because macadamia oil is at least one potentially large source of palmitoleic acid, we tested its effect on plasma lipid levels against two other dietary fatty acids, oleic acid and palmitic acid. The dietary adjustments, through the use of supplements, provided comparisons of the three test fatty acids in which palmitoleic could be judged as behaving either like a saturated or a monounsaturated acid. Thirty-four hypercholesterolemic men ate the three test diets in random order in 3-week periods. Plasma total cholesterol and low density lipoprotein (LDL) cholesterol concentrations were similar with palmitoleic and palmitoleic acids and significantly higher than with oleic acid. High density lipoprotein (HDL) cholesterol was significantly lower with palmitoleic than with palmitic acid. The study confirms that, at least in hypercholesterolemic men, a modest increase in palmitic acid (+4% en) raises LDL cholesterol relative to oleic acid (+3% en), even when dietary cholesterol is low (< 165 mg/day). Palmitoleic acid (+4% en) behaves like a saturated and not a monounsaturated fatty acid in its effect on LDL cholesterol.
Clinical References on Mulungu (Piscidia erythrina)
Della Loggia R, et al. Isoflavones as spasmolytic principles of Piscidia erythrina. Prog Clin Biol Res, 1988
(Abstract Available)
Della Loggia R, et al. [Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them] Riv Neurol, 1981 Sep-Oct,
[Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them]
Della Loggia R; Tubaro A; Redaelli C
Riv Neurol, 51: 5, 1981 Sep-Oct, 297-310
Abstract
Some activities of seven vegetable extracts and an association of them given by oral route were tested on the C.N.S. of the mouse. Among these, Crataegus oxyacantha and, less clearly, Valeriana officinalis show some sedative activity, whereas the extract from Passiflora incarnata gives some anxiolytic effect. Matricaria chamomilla and Piscidia erythrina stand in an intermediate position between the previous ones. Hyoscyamus niger proved to be active in only one of the tests performed, whereas Atropa belladonna did not show any activity on the C.N.S. The association of the seven extracts seemed to act in a synergetic way, the resulting activity being sedative at high dosage and anxiolytic at low dosage.
Clinical References on Muira Puama (Ptychopetalum olacoides)
Wayneberg, J., Male Sexual Asthenia- Interest In A Traditional Plant-Derived Medication: "Testor-plus" Full clinical trial available
Waynberg J, Aphrodisiacs: Contributions to the clinical evaluation of the traditional use of Ptychopetalum. First International Congress on Ethnopharmacology, France, June 1990.
Murray, M., "Yohimbine vs. Muira puama in the treatment of erectile dysfunction"
Am Jn of Nat Med, November 1994, Vol. 1, No. 3, Page 8.
Auterhoff H, et al. [Lipophilic constituent of Muira puama] Arch Pharm Ber Dtsch Pharm Ges, 1971 Mar
Pankow E, et al. [Contents of Muira puama. 2] (Arch Pharm Ber Dtsch Pharm Ges, 1969 Mar
Auterhoff H, et al. [Contents of Muira puama] Arch Pharm Ber Dtsch Pharm Ges, 1968 Jul
Iwasa J, et al. [Studies on the constituents of muira puama] Yakugaku Zasshi, 1969 Aug
† The statements contained herein have not been evaluated by the
Food and Drug Administration. The information contained in this web file is intended for education, entertainment and information purposes only. This information is not intended to be used to diagnose, prescribe or replace proper medical care. The plants described herein are not
intended to treat, cure, diagnose, mitigate or prevent any disease and no medical claims are made.
Please refer to our Conditions of Use for using this web file and web site.
© Copyrighted 1996
to present. Raintree Nutrition, Inc., Carson City, NV 89701. All rights reserved.
Please read the Conditions of Use, Copyright Statement and our Privacy Policy for this web page and web site.